Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.86 EUR
Change Today +0.011 / 1.29%
Volume 1.0K
VCC On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:39 AM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

vical inc (VCC) Snapshot

Open
€0.87
Previous Close
€0.85
Day High
€0.87
Day Low
€0.86
52 Week High
01/12/15 - €1.05
52 Week Low
12/16/14 - €0.70
Market Cap
78.8M
Average Volume 10 Days
725.0
EPS TTM
--
Shares Outstanding
91.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VICAL INC (VCC)

vical inc (VCC) Related Bloomberg News

View More Bloomberg News

vical inc (VCC) Related Businessweek News

No Related Businessweek News Found

vical inc (VCC) Details

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its product candidates include CyMVectin prophylactic vaccine for cytomegalovirus (CMV), which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic vaccine for herpes simplex virus type 2, which is under Phase 1/2 clinical trial to prevent and protect against recurring flare-ups, reduce viral shedding, and transmission. The company, through corporate collaborations, is also developing ASP0113, which is under Phase III clinical trial for prevention of CMV reactivation in stem cell transplant recipients, as well as in Phase II clinical trial for prevention of CMV infection in kidney transplant recipients; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to enhance survival time of dogs with oral melanoma. In addition, Vical Incorporated, through government collaboration, is developing Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all four dengue serotypes. Further, it engages in contract manufacturing of plasmid investigational products for various clients. The company was founded in 1987 and is headquartered in San Diego, California.

68 Employees
Last Reported Date: 02/26/15
Founded in 1987

vical inc (VCC) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $821.0K
Chief Accounting Officer and Vice President o...
Total Annual Compensation: $292.2K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $344.8K
Vice President of Vaccine Research
Total Annual Compensation: $337.8K
Compensation as of Fiscal Year 2014.

vical inc (VCC) Key Developments

Vical Incorporated - Special Call

Vical Incorporated - Special Call

Vical Incorporated Provides Cash Burn Guidance for 2015

Vical Incorporated provided cash burn guidance for 2015. For 2015, the company expects cash burn guidance, which remains at between $12 million and $15 million.

Vical Incorporated Reports Financial Results for the Three Months and Twelve Months Ended December 31, 2014

Vical Incorporated reported financial results for the three months and twelve months ended December 31, 2014. Net loss for the fourth quarter of 2014 was $4.6 million, or $0.05 per share, compared with a net loss of $2.2 million, or $0.03 per share, for the fourth quarter of 2013. The increase in the company's net loss compared to the fourth quarter of 2013 was due primarily to increased expenses related to its HSV-2 program. Revenues were $4.8 million, compared with revenues of $3.1 million for the fourth quarter of 2013, reflecting higher revenues from Astellas Pharma Inc. for development and manufacturing services performed under the company's ASP0113 collaborative agreements. Loss from operations was $4.7 million compared to $2.22 million a year ago. Net loss was $16.5 million, or $0.19 per basic and diluted share, compared with a net loss of $31.24 million, or $0.36 per basic and diluted share a year ago. Revenues were $15.217 million, compared with revenues of $7.72 million a year ago. Loss from operations was $16.63 million compared to $31.4 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VCC:GR €0.86 EUR +0.011

VCC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dynavax Technologies Corp $23.48 USD -0.10
Eurocine Vaccines AB kr2.73 SEK -0.05
GenVec Inc $2.81 USD -0.06
Inovio Pharmaceuticals Inc $10.32 USD +0.28
Peregrine Pharmaceuticals Inc $1.41 USD +0.02
View Industry Companies
 

Industry Analysis

VCC

Industry Average

Valuation VCC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.6x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VICAL INC, please visit www.vical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.